Précis: Using iCare Home2 (iCare, Finland) rebound tonometry, self-measurement of intraocular pressure has demonstrated good reliability and ease of use. Purpose: To investigate the reliability and repeatability of self-measured intraocular pressure (IOP) with rebound tonometry using iCare Home2. Patients and Methods: One hundred four patients out of 110 consecutive patients were recruited for this observational cross-sectional study. One randomly selected eye from each patient underwent 6 consecutive IOP measurements with Goldmann applanation tonometry (GAT), iCare IC200, and iCare Home2. Every eye was tested twice with each device, in random order, by an ophthalmologist for GAT and IC200, and by the patient itself for Home2. In addition, central corneal thickness (CCT) has been collected. The reliability of Home2 has been tested by calculating limits of agreement (LoA) between self-measured and physician-measured IOP, using the Bland-Altman analysis. The repeatability of each device has been tested by calculating the limits of repeatability (LoR) with the same method. Pearson correlation coefficient was used to determine the correlation between differences in IOP measurements and CCT. Results: The mean difference between GAT and iCare Home2 was −0.28±1.57 mmHg (P=0.070), 95%-LoA: (−3.36 to 2.79 mmHg). The mean difference between IC200 and iCare Home2 was 0.92±1.48 mmHg (P<0.0001), 95%-LoA (−1.98 to 3.82 mmHg). The mean difference between the first and second measurements with GAT, iCare IC200, and iCare Home2 measurements was 0.21±0.98 mmHg (P=0.03), −0.02±1.11 mmHg (P=0.88) and −0.23±1.04 mmHg (P=0.05). Conclusions: Self-measured IOP with rebound tonometry showed good reliability and repeatability when compared with physician-measured IOP with both standard GAT and rebound tonometry.

Objectives: To evaluate the retinal ganglion cell (RGC) function and neural conduction along the visual pathways after treatment with Citicoline plus Nicotinamide oral solution in patients with open angle glaucoma (OAG). Methods: Thirty OAG patients (mean age ± standard deviation: 62.588 ± 6.022 years, IOP < 18 mmHg with medical therapy) were enrolled. Of these, 20 OAG patients (providing 20 eyes) were treated with Citicoline plus Nicotinamide oral solution (Kron^®, Omikron Italia) (Citicoline plus Nicotinamide group), and 10 OAG patients (providing 10 eyes) were treated with an oral placebo (Placebo group). In all participants, Humphrey 24-2 visual field (HFA 24-2), pattern electroretinogram (PERG), visual evoked potentials (VEP) and retinal nerve fiber layer thickness (RNFL-T) were assessed at baseline and at the end of the 3-month period of treatment. Results: PERG and VEP data obtained from 28 patients were included in the final analysis, while all the patients were included in the visual field and RNFL-T analyses. At baseline, both groups showed HFA 24-2 mean deviation (MD), PERG, VEP and RNFL-T values not statistically (ANOVA, p > 0.05) different. After 3 months of Citicoline plus Nicotinamide oral solution treatment, a significant (p < 0.05) increase in PERG P50-N95 and VEP N75-P100 amplitudes, and a significant (p < 0.05) shortening of VEP P100 implicit times were found. The shortening of VEP P100 implicit times was not significantly correlated (p > 0.01) with the increase in PERG P50-N95 amplitude. Conversely, in the Placebo group, no significant changes in PERG and VEP values were found. The HFA MD and RNFL-T changes were not significantly different (p > 0.05) between groups. Conclusions: In OAG patients, treatment with Citicoline plus Nicotinamide oral solution for three months induces RGC functional enhancement (increase in PERG amplitude) and improves the neural conduction along the visual pathways (shortening of VEP implicit time and increased amplitude), without significant changes in visual field or RNFL-T.